Workflow
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
Eton PharmaceuticalsEton Pharmaceuticals(US:ETON) Globenewswire·2025-04-28 18:50
  • NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-600, Et ...